This suggests that the levels of ANGPTL3 may have a much greater impact on CAD in hypertensive patients than in people without hypertension, which may be due to the fact that patients with hypertension are often complicated with obesity and dyslipidemia,33 thus affecting the levels of ANGPTL3, which are mainly secreted by adipose tissue. Here, ANGPTL3 is linked to obesity disorder.